Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.

Celine Johanna van de LaarMartijn A H Oude VoshaarWalid K H FakhouriLiliana Zaremba-PechmannFrancesco De LeonardisInmaculada De La TorreMart A F J Van De Laar

Published in: ClinicoEconomics and outcomes research : CEOR (2020)

Results suggest that the use of a JAK1/JAK2 inhibitor instead of a bDMARD in a T2T approach is cost-effective in csDMARD refractory RA patients.

Keyphrases

rheumatoid arthritis
disease activity
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
ankylosing spondylitis
interstitial lung disease
prognostic factors
emergency department
patient reported outcomes
drug induced
adverse drug